Skip to main content
Erschienen in: Inflammation 2/2014

01.04.2014

Interleukin 6(-174G/C) Variant and its Circulating Levels in Coronary Artery Disease Patients and Their First Degree Relatives

verfasst von: Rajesh Kumar Galimudi, Mrudula K. Spurthi, Chiranjeevi Padala, Kishore G. Kumar, Saraswati Mudigonda, Srilatha G. Reddy, Mohini T. Aiyengar, Sanjib K. Sahu, Surekha H. Rani

Erschienen in: Inflammation | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Interleukin-6 (IL-6) a pleiotropic cytokine is a central mediator of inflammation in the pathogenesis of coronary artery disease (CAD). Our aim is to evaluate the serum levels of IL-6 and C-reactive protein (CRP) and to analyze the IL-6 polymorphism in CAD patients and to identify the first-degree relatives (FDRs) at risk of the disease in comparison with healthy controls. Estimation of IL-6 levels by enzyme-linked immunosorbent assay (ELISA) and CRP by latex reagent kit method, and genotyping of IL6 gene variants −174 (G>C) was carried out by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 600 subjects. IL-6 and CRP levels were significantly high in patients followed by FDRs compared to controls. The frequency of the IL-6 genotype was significantly different between cases, FDRs and controls and association of serum IL-6 levels with genotype found to be significant in CC genotype compared to GC and GG at p < 0.01 in CAD patients and FDRs, while there is no significant difference observed in controls. The study shows the importance of inflammation in the pathogenesis of CAD and predicts the risk of future coronary events in healthy asymptomatic FDRs.
Literatur
1.
Zurück zum Zitat Svati, H.S., J.F. Neil, Lisheng, R.C. David, H.S. David, H. Carol, J. Jessica, N. Sarah, W. Liyong, J.C. Jessica, M. Michael, S.G. Geoffrey, C.C. David, J.H.J. Christopher, V. Jeffery, H.S.J. Michael, B.G. Christopher, B.N. Christopher, G.G. Simon, J.G.C. Pascal, E.K. William, and R.H. Elizabeth. 2009. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genetics 5(1): e1000318.CrossRef Svati, H.S., J.F. Neil, Lisheng, R.C. David, H.S. David, H. Carol, J. Jessica, N. Sarah, W. Liyong, J.C. Jessica, M. Michael, S.G. Geoffrey, C.C. David, J.H.J. Christopher, V. Jeffery, H.S.J. Michael, B.G. Christopher, B.N. Christopher, G.G. Simon, J.G.C. Pascal, E.K. William, and R.H. Elizabeth. 2009. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genetics 5(1): e1000318.CrossRef
2.
Zurück zum Zitat Rajeshwari, R.R., T.A. Nicklas, H.J. Pownall, and G.S. Berenson. 2005. Cardiovascular diseases—A major health risk in Asian Indians. Nutrition Research 25: 515–533.CrossRef Rajeshwari, R.R., T.A. Nicklas, H.J. Pownall, and G.S. Berenson. 2005. Cardiovascular diseases—A major health risk in Asian Indians. Nutrition Research 25: 515–533.CrossRef
3.
Zurück zum Zitat Apurva, S., M. Ranjit, S. Swarup, R. Rani, D. Gargi, R. Himanshu, D. Shoba, S. Aarti, D. Pradnya, T. Seema, and F.A. Tester. 2011. Prevalence of metabolic syndrome in urban India. Hindawi Publishing Corporation, Cholesterol. Volume, Article ID 920983, 7 pp. Apurva, S., M. Ranjit, S. Swarup, R. Rani, D. Gargi, R. Himanshu, D. Shoba, S. Aarti, D. Pradnya, T. Seema, and F.A. Tester. 2011. Prevalence of metabolic syndrome in urban India. Hindawi Publishing Corporation, Cholesterol. Volume, Article ID 920983, 7 pp.
4.
Zurück zum Zitat Kasliwal, R.R., A. Kulshreshtha, S. Agrawal, M. Bansal, and N. Trehan. 2006. Prevalence of cardiovascular risk factors in Indian patients undergoing coronary artery bypass surgery. JAPI 54: 371–375.PubMed Kasliwal, R.R., A. Kulshreshtha, S. Agrawal, M. Bansal, and N. Trehan. 2006. Prevalence of cardiovascular risk factors in Indian patients undergoing coronary artery bypass surgery. JAPI 54: 371–375.PubMed
5.
Zurück zum Zitat Yeh, E.T.H., H.V. Anderson, V. Pasceri, and J.T. Willerson. 2001. C-reactive protein linking inflammation to cardiovascular complications. Circulation 104: 974–975.PubMedCrossRef Yeh, E.T.H., H.V. Anderson, V. Pasceri, and J.T. Willerson. 2001. C-reactive protein linking inflammation to cardiovascular complications. Circulation 104: 974–975.PubMedCrossRef
6.
Zurück zum Zitat Ross, R. 1999. Atherosclerosis: An inflammatory disease. New England Journal of Medicine 340: 115–126.PubMedCrossRef Ross, R. 1999. Atherosclerosis: An inflammatory disease. New England Journal of Medicine 340: 115–126.PubMedCrossRef
7.
Zurück zum Zitat Sven, W., S. Michaela, S. Kerstin, S. Andreas, S. Bernhard, B. Michael, and N. Georg. 2004. Interleukin-6 induces oxidative stress and endothelial; dysfunction by overexpression of the angiotensin II type 1 receptor. Circulation Research 94: 534–541.CrossRef Sven, W., S. Michaela, S. Kerstin, S. Andreas, S. Bernhard, B. Michael, and N. Georg. 2004. Interleukin-6 induces oxidative stress and endothelial; dysfunction by overexpression of the angiotensin II type 1 receptor. Circulation Research 94: 534–541.CrossRef
8.
Zurück zum Zitat Armstrong, E.J., D.A. Morrow, and M.S. Sabatine. 2006. Inflammatory biomarkers in acute coronary syndromes: Part I. Introduction and cytokines. Circulation 113: e72–e75.PubMedCrossRef Armstrong, E.J., D.A. Morrow, and M.S. Sabatine. 2006. Inflammatory biomarkers in acute coronary syndromes: Part I. Introduction and cytokines. Circulation 113: e72–e75.PubMedCrossRef
9.
Zurück zum Zitat Bennermo, M., C. Held, S. Stemme, C.G. Ericsson, A. Silveira, F. Green, and P. Tornvall. 2004. Genetic predisposition of the interleukin-6 response to inflammation: Implications for a variety of major diseases? Clinical Chemistry 50(11): 2136–2140.PubMedCrossRef Bennermo, M., C. Held, S. Stemme, C.G. Ericsson, A. Silveira, F. Green, and P. Tornvall. 2004. Genetic predisposition of the interleukin-6 response to inflammation: Implications for a variety of major diseases? Clinical Chemistry 50(11): 2136–2140.PubMedCrossRef
10.
Zurück zum Zitat Lahiri, D., and J. Nurnberger. 1991. A rapid non enzymatic method for preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research 19: 5444.PubMedCentralPubMedCrossRef Lahiri, D., and J. Nurnberger. 1991. A rapid non enzymatic method for preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research 19: 5444.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Ross, R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 802–809.CrossRef Ross, R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 802–809.CrossRef
12.
Zurück zum Zitat Woods, D.J.B., S.E. Humphries, and H.E. Montgomery. 2000. Genetics of inflammation and risk of coronary artery disease: The central role of interleukin-6. European Heart Journal 21: 1574–1583.PubMedCrossRef Woods, D.J.B., S.E. Humphries, and H.E. Montgomery. 2000. Genetics of inflammation and risk of coronary artery disease: The central role of interleukin-6. European Heart Journal 21: 1574–1583.PubMedCrossRef
13.
Zurück zum Zitat Connelly, J.J., T. Wang, J.E. Cox, C. Haynes, L. Wang, S.H. Shah, D.R. Crosslin, A.B. Hale, S. Nelson, D.C. Crossman, C.B. Granger, J.L. Haines, C.J.H. Jones, J.M. Vance, P.J. Goldschmidt-Clermont, W.E. Kraus, E.R. Hauser, and S.G. Gregory. 2006. GATA2 is associated with familial early-onset coronary artery disease. PLoS Genetics 2(8): e139.PubMedCentralPubMedCrossRef Connelly, J.J., T. Wang, J.E. Cox, C. Haynes, L. Wang, S.H. Shah, D.R. Crosslin, A.B. Hale, S. Nelson, D.C. Crossman, C.B. Granger, J.L. Haines, C.J.H. Jones, J.M. Vance, P.J. Goldschmidt-Clermont, W.E. Kraus, E.R. Hauser, and S.G. Gregory. 2006. GATA2 is associated with familial early-onset coronary artery disease. PLoS Genetics 2(8): e139.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Mendall, M.A., P. Patel, M. Asante, L. Ballam, J. Morris, D.P. Strachan, A.J. Camm, and T.C. Northfield. 1997. Relation of serum levels of cytokines to cardiovascular risk factors and coronary heart disease. Heart 78: 273–277.PubMedCentralPubMed Mendall, M.A., P. Patel, M. Asante, L. Ballam, J. Morris, D.P. Strachan, A.J. Camm, and T.C. Northfield. 1997. Relation of serum levels of cytokines to cardiovascular risk factors and coronary heart disease. Heart 78: 273–277.PubMedCentralPubMed
15.
Zurück zum Zitat Luc, G., J.-M. Bard, I. Juhan-Vague, J. Ferrieres, A. Evans, P. Amouyel, D. Arveiler, J.-C. Fruchart, D. Ducimetiere, and on behalf of the PRIME Study Group. 2003. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease. The PRIME Study. Arteriosclerosis, Thrombosis, and Vascular Biology 23: 1255–1261.PubMedCrossRef Luc, G., J.-M. Bard, I. Juhan-Vague, J. Ferrieres, A. Evans, P. Amouyel, D. Arveiler, J.-C. Fruchart, D. Ducimetiere, and on behalf of the PRIME Study Group. 2003. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease. The PRIME Study. Arteriosclerosis, Thrombosis, and Vascular Biology 23: 1255–1261.PubMedCrossRef
16.
Zurück zum Zitat Humphries, S.E., L.A. Luong, M.S. Ogg, E. Hawe, and G.J. Miller. 2001. The interleukin-6–174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. European Heart Journal 22: 2243–2252.PubMedCrossRef Humphries, S.E., L.A. Luong, M.S. Ogg, E. Hawe, and G.J. Miller. 2001. The interleukin-6–174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. European Heart Journal 22: 2243–2252.PubMedCrossRef
17.
Zurück zum Zitat Ridker, P.M., J.E. Buring, J. Shih, M. Matias, and C.H. Hennekens. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731–733.PubMedCrossRef Ridker, P.M., J.E. Buring, J. Shih, M. Matias, and C.H. Hennekens. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731–733.PubMedCrossRef
18.
Zurück zum Zitat Bo, I.M., A.S. Raspo, E. Morra, G. Isaia, M. Cassader, E. Fabris, and L. Poli. 2004. Body fat and C-reactive protein levels in healthy non-obese men. Nutrition, Metabolism, and Cardiovascular Diseases 14: 66–72.PubMedCrossRef Bo, I.M., A.S. Raspo, E. Morra, G. Isaia, M. Cassader, E. Fabris, and L. Poli. 2004. Body fat and C-reactive protein levels in healthy non-obese men. Nutrition, Metabolism, and Cardiovascular Diseases 14: 66–72.PubMedCrossRef
19.
Zurück zum Zitat Koenig, W., M. Sund, M. Frohlich, H.G. Fischer, H. Lowe, A. Doring, W.L. Hutchinson, and M.B. Pepys. 1999. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237–242.PubMedCrossRef Koenig, W., M. Sund, M. Frohlich, H.G. Fischer, H. Lowe, A. Doring, W.L. Hutchinson, and M.B. Pepys. 1999. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237–242.PubMedCrossRef
20.
Zurück zum Zitat Yudkin, J.S., C.D.A. Stehouwer, J.J. Emeis, and S.W. Coppack. 1999. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction a potential role for cytokines originating from adipose tissue? Arteriosclerosis, Thrombosis, and Vascular Biology 19: 972–978.PubMedCrossRef Yudkin, J.S., C.D.A. Stehouwer, J.J. Emeis, and S.W. Coppack. 1999. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction a potential role for cytokines originating from adipose tissue? Arteriosclerosis, Thrombosis, and Vascular Biology 19: 972–978.PubMedCrossRef
21.
Zurück zum Zitat Josemanuel, F.R., V. Montserrat, R. Cristobal, G. Cristina, B. Montserrat, V. Joan, and R. Wifredo. 2001. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. Journal of Clinical Endocrinology and Metabolism 86: 1154–1159.CrossRef Josemanuel, F.R., V. Montserrat, R. Cristobal, G. Cristina, B. Montserrat, V. Joan, and R. Wifredo. 2001. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. Journal of Clinical Endocrinology and Metabolism 86: 1154–1159.CrossRef
22.
Zurück zum Zitat Dimitris, A.P., L.W. Ronald, C.M. Stavros, and P.C. George. 1998. The pathophysiologic roles of interleukin-6 in human disease. Annals of Internal Medicine 128: 127–137.CrossRef Dimitris, A.P., L.W. Ronald, C.M. Stavros, and P.C. George. 1998. The pathophysiologic roles of interleukin-6 in human disease. Annals of Internal Medicine 128: 127–137.CrossRef
23.
Zurück zum Zitat Aukrust, P., T. Ueland, E. Lien, et al. 1999. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology 83: 376–382.PubMedCrossRef Aukrust, P., T. Ueland, E. Lien, et al. 1999. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology 83: 376–382.PubMedCrossRef
24.
Zurück zum Zitat Liu, Y., S.Y. Berthier, M.D. Fallin, N.E. Fink, R.P. Tracy, and M.J. Klag. 2006. IL-6 Haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. Journal of the American Society of Nephrology 17: 863–870.PubMedCrossRef Liu, Y., S.Y. Berthier, M.D. Fallin, N.E. Fink, R.P. Tracy, and M.J. Klag. 2006. IL-6 Haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. Journal of the American Society of Nephrology 17: 863–870.PubMedCrossRef
25.
Zurück zum Zitat Danesh, J., K. Stephen, G.M. Andrea, S. Nadeem, W. Angela, B.A. Sara, W. Frances, P.T.H. Julian, L. Lucy, E. Gudny, R. Ann, H.W. Peter, D.O.L. Gordon, and G. Vilmundur. 2008. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review. PLoS Medicine 5(4): e78.PubMedCentralPubMedCrossRef Danesh, J., K. Stephen, G.M. Andrea, S. Nadeem, W. Angela, B.A. Sara, W. Frances, P.T.H. Julian, L. Lucy, E. Gudny, R. Ann, H.W. Peter, D.O.L. Gordon, and G. Vilmundur. 2008. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review. PLoS Medicine 5(4): e78.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Ridker, P.R., R. Nader, J.S. Meir, and H.H. Charles. 2000. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men; atherogenesis. Circulation 101: 1767–1772.PubMedCrossRef Ridker, P.R., R. Nader, J.S. Meir, and H.H. Charles. 2000. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men; atherogenesis. Circulation 101: 1767–1772.PubMedCrossRef
27.
Zurück zum Zitat Mohlig, M., B. Heiner, S. Joachim, O. Martin, K. Anja, E.V.A. Fisher, M.B. Manuela, R. Michael, H. Kurt, and F.H.P. Andreas. 2004. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 89: 1885–1890.PubMedCrossRef Mohlig, M., B. Heiner, S. Joachim, O. Martin, K. Anja, E.V.A. Fisher, M.B. Manuela, R. Michael, H. Kurt, and F.H.P. Andreas. 2004. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 89: 1885–1890.PubMedCrossRef
28.
Zurück zum Zitat Jones, K.G., D.J. Brull, M. Sian, L.C. Brown, S.E. Humphries, and J.T. Powell. 2001. Interleukin-6 and the prognosis of abdominal aortic aneurysm. Circulation 103: 2260–2265.PubMedCrossRef Jones, K.G., D.J. Brull, M. Sian, L.C. Brown, S.E. Humphries, and J.T. Powell. 2001. Interleukin-6 and the prognosis of abdominal aortic aneurysm. Circulation 103: 2260–2265.PubMedCrossRef
29.
Zurück zum Zitat Georges, J.L., V. Loukaci, O. Poirier, A. Evans, G. Luc, D. Arveiler, J.B. Ruidavets, F. Cambien, and L. Tiret. 2001. Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: The ECTIM study. Journal of Molecular Medicine 79: 300–305.PubMedCrossRef Georges, J.L., V. Loukaci, O. Poirier, A. Evans, G. Luc, D. Arveiler, J.B. Ruidavets, F. Cambien, and L. Tiret. 2001. Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: The ECTIM study. Journal of Molecular Medicine 79: 300–305.PubMedCrossRef
30.
Zurück zum Zitat Terry, C.F., V. Loukaci, and F.R. Green. 2000. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. Journal of Biological Chemistry 275: 18138–18144.PubMedCrossRef Terry, C.F., V. Loukaci, and F.R. Green. 2000. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. Journal of Biological Chemistry 275: 18138–18144.PubMedCrossRef
31.
Zurück zum Zitat Fishman, D., G. Faulds, R. Jeffery, V. Mohamed-Ali, J.S. Yudkin, S. Humphries, et al. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. Journal of Clinical Investigation 102: 1369–1376.PubMedCentralPubMedCrossRef Fishman, D., G. Faulds, R. Jeffery, V. Mohamed-Ali, J.S. Yudkin, S. Humphries, et al. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. Journal of Clinical Investigation 102: 1369–1376.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Roger, R.W., C.H. Steven, H. Gerardo, A.P. Michael, T.B. Jeannette, H. Millicent, M.C. Robert, W. Joan, and N.H. Paul. 2001. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research. (The Health Family Tree Study and the NHLBI Family Heart Study). American Journal of Cardiology 87: 129–135.CrossRef Roger, R.W., C.H. Steven, H. Gerardo, A.P. Michael, T.B. Jeannette, H. Millicent, M.C. Robert, W. Joan, and N.H. Paul. 2001. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research. (The Health Family Tree Study and the NHLBI Family Heart Study). American Journal of Cardiology 87: 129–135.CrossRef
Metadaten
Titel
Interleukin 6(-174G/C) Variant and its Circulating Levels in Coronary Artery Disease Patients and Their First Degree Relatives
verfasst von
Rajesh Kumar Galimudi
Mrudula K. Spurthi
Chiranjeevi Padala
Kishore G. Kumar
Saraswati Mudigonda
Srilatha G. Reddy
Mohini T. Aiyengar
Sanjib K. Sahu
Surekha H. Rani
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 2/2014
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9742-8

Weitere Artikel der Ausgabe 2/2014

Inflammation 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.